IGM Biosciences, Inc.
NASDAQ: IGMS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mary Beth Harler
- Employees
- 149
- Headquarters
- Mountain View, United States
- IPO year
- 2019
- Market cap
- $77.5M
- Website
- https://igmbio.com
Loading IGMS…
Loading profile data…Frequently asked questions about IGMS
What does IGM Biosciences, Inc. (IGMS) do?
IGM Biosciences, Inc. operates as a biotechnology firm dedicated to advancing Immunoglobulin M (IgM) antibodies. These novel therapeutic agents are being developed for a broad spectrum of conditions, including various cancers, infectious ailments, and autoimmune and inflammatory disorders. The company's most advanced experimental treatment is IG...
Where does IGMS trade?
IGM Biosciences, Inc. (IGMS) trades on the NASDAQ Global Select.
What sector is IGMS in?
IGM Biosciences, Inc. (IGMS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IGM Biosciences, Inc.?
Mary Beth Harler is the chief executive officer of IGM Biosciences, Inc. (IGMS).
Where is IGM Biosciences, Inc. headquartered?
IGM Biosciences, Inc. is headquartered in United States.
Does IGMS pay a dividend?
IGM Biosciences, Inc. (IGMS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IGMS go public?
IGM Biosciences, Inc. (IGMS) completed its initial public offering in 2019.